Gastric Tumor Microenvironment

Rojas, Armando; Araya, Paulina; González, Ileana; Morales, Erik

doi:10.1007/978-3-030-36214-0_2

Cited by 64 publications

(43 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, these cells seem to be involved in the secretion of R-spondin3, taking part in stem cell activity; moreover, during the process of mucosal inflammation and regeneration, myofibroblasts have been observed to promote proliferation and stem cell function [87,88]. Likewise, studies on GC murine models have highlighted that nearly one-fifth of the overall number of CAFs could originate from MSCs derived from bone marrow [89,90]. These findings have also been reported in patients with GCs and/or rectal adenomas following bone marrow transplantation [33,91].…”

Section: Cancer-associated Fibroblastsmentioning

confidence: 99%

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications

Rihawi

Ricci

Rizzo

et al. 2021

IJMS

105

View full text Add to dashboard Cite

Gastric cancer (GC) represents the fifth most frequently diagnosed cancer worldwide, with a poor prognosis in patients with advanced disease despite many improvements in systemic treatments in the last decade. In fact, GC has shown resistance to several treatment options, and thus, notable efforts have been focused on the research and identification of novel therapeutic targets in this setting. The tumor microenvironment (TME) has emerged as a potential therapeutic target in several malignancies including GC, due to its pivotal role in cancer progression and drug resistance. Therefore, several agents and therapeutic strategies targeting the TME are currently under assessment in both preclinical and clinical studies. The present study provides an overview of available evidence of the inflammatory TME in GC, highlighting different types of tumor-associated cells and implications for future therapeutic strategies.

show abstract

Section: Cancer-associated Fibroblastsmentioning

confidence: 99%

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications

Rihawi

Ricci

Rizzo

et al. 2021

IJMS

105

View full text Add to dashboard Cite

show abstract

“…ese results are consistent with our predictions, suggesting that high-degree compounds might play an important role in the treatment of GC. e occurrence and development of the tumor is not only related to its own malignant proliferation but also closely related to TME [31]. TME is a highly dynamic and heterogeneous composition of immune cells, fibroblasts, precursor cells, endothelial cells, signaling molecules, and extracellular matrix components [32].…”

Section: Discussionmentioning

confidence: 99%

“…(1) Epithelial cell signaling in Helicobacter pylori infection pathway: H. pylori exposure results in a chronic inflammation microenvironment which is strongly linked to GC [31]. Study has shown that the extract of RRER has the antibacterial activity Node color is displayed in a gradient from red to green in descending order of the P value.…”

Section: Discussionmentioning

confidence: 99%

An Investigation of the Antigastric Cancer Effect in Tumor Microenvironment of Radix Rhei Et Rhizome: A Network Pharmacology Study

Wang

Zhu

Yang

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Tumor microenvironment (TME) takes a vital effect on the occurrence and development of cancer. Radix Rhei Et Rhizome (RRER, Da-Huang in pinyin), a classical Chinese herb, has been widely used in gastric cancer (GC) for many years in China. However, inadequate systematic studies have focused on the anti-GC effect of RRER in TME. This study intended to uncover the mechanism of it by network pharmacology. Methods. We collected compounds and targets of RRER from traditional Chinese medicine system pharmacology database and analysis platform (TCMSP) and SwissTargetPrediction. GC targets were obtained from GeneCards. Protein-protein interaction (PPI) network and RRER-GC-target network were built by STRING and Cytoscape 3.2.1. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed using Database for Annotation, Visualization, and Integrated Discovery (DAVID). Results. We obtained 92 compounds of RRER. A total of 10 key compounds and 20 key targets were selected by “RRER-GC-target network” topological analysis. GO analysis showed that the biological process mainly involved in response to the tumor necrosis factor, positive regulation of fibroblast proliferation, and DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest. Molecular functions included cyclin-dependent protein serine/threonine kinase activity, RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding, and transmembrane receptor protein tyrosine kinase activity. Cellular components mainly were centrosome, cell surface, and membrane. KEGG pathway enrichment results mainly involved in the p53 signaling pathway, estrogen signaling pathway, and regulation of lipolysis in adipocytes. Conclusion. This study explored the anti-GC mechanism of RRER from the perspective of TME based on network pharmacology, which contributed to the development and application of RRER.

show abstract

“…In GC, there is an active cross-talk between different cells acting in the microenvironment, such as tumor-infiltrated lymphocyte, macrophages, neutrophils, and fibroblasts. These interactions can modulate the genetic and epigenetic changes in the extracellular matrix, leading to differential responses to chemotherapy and cancer progression [63, 64]. In particular, some trials have reported a better prognosis in patients with high CD8+ T cell levels and fewer FOXP3+ regulatory T cells and in patients with a low neutrophil-to-lymphocyte ratio [65] or platelet-to-lymphocyte ratio [66], in particular in metastatic GC treated with chemotherapy.…”

Section: Future Perspectivesmentioning

confidence: 99%

Biomarkers for Precision Treatment in Gastric Cancer

Petrillo

Smyth

2020

Visc Med

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is one of the most lethal cancers worldwide. Although GC was historically considered a single entity within the organ of origin, nowadays it is acknowledged that GC represents a heterogeneous disease. Nevertheless, in this field there is still a lack of biomarkers able to guide the choice of the best treatment options for each patient. This review aims to summarize the prognostic and predictive biomarkers evaluated in GC and their role as a guide for treatment for precision medicine. Summary: Human epidermal growth factor receptor 2 overexpression represents the only predictive molecular biomarker validated in GC, while its prognostic role is still controversial. Microsatellite instability and Epstein-Barr virus status are promising for prediction of the response to immunotherapy. The role of other biomarkers (ctDNA, programmed death ligand 1 [PD-L1], and TMB), as well as the practical application of molecular classifications, requires further evaluation before use in clinical practice. 18-FDG-PET scan could be useful as a predictive tool in non-metastatic GC patients receiving a perioperative approach. Finally, the tumor microenvironment may have an evolving role in the future. Key Messages: GC is a heterogeneous disease and targeted approaches are needed. The finding of prognostic and predictive factors is a hot topic in the field of GC personalized medicine.

show abstract

Gastric Tumor Microenvironment

Cited by 64 publications

References 121 publications

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications

Tumor-Associated Macrophages and Inflammatory Microenvironment in Gastric Cancer: Novel Translational Implications

An Investigation of the Antigastric Cancer Effect in Tumor Microenvironment of Radix Rhei Et Rhizome: A Network Pharmacology Study

Biomarkers for Precision Treatment in Gastric Cancer

Contact Info

Product

Resources

About